Among cytogenetic aberrations in Ewing's sarcoma (ES) and peripheral primitive neuroectodermal tumours (pPNET), recently referred to as 'Ewing tumours' (ET), the reciprocal translocation between the long arms of chromosomes 11 and 22, t(I 1;22)(q24;q12) occurs in 83% of cases. In an additional 9% complex translocations involving chromosome 22 have been identified (Aurias et al., 1983; Turc-Carel et al., 1983; Whang-Peng et al., 1984) . Moreover, tumour cells of ES and pPNET are well characterised by the extraordinary high expression of the pseudoautosomal MIC2P3-32 gene (Kovar et al., 1990) , which represents a highly selective feature of these cells, making an assignment of these small round-cell tumours as one entity even more likely (Ambros et al., 1991) .
The recent cloning of the chromosome breakpoints of the ET-specific t(I 1;22) translocation revealed that the sites of rearrangement were localised within two regions, EWSR1 and EWSR2, on chromosome 22 and 11 respectively (Zucman et al., 1992) . On chromosome 22, EWSR1 is nested within a novel gene of unknown function, EWS . The gene involved in the translocation on chromosome 11 was revealed to encode the human homologue of murine FLI-l, a member of the ETS family of transcription factors. In mice, FLI-1 resides at the insertion site of Friend murine leukaemia virus in induced erythroleukaemias. Proviral integration causes FLI-1 activation and consequently neoplastic transformation of erythroid progenitor cells. As a result of the gene rearrangement in human ET cells, the C-terminal FLI-1 portion is constitutively expressed from the EWS gene promoter as part of a chimaeric protein. In addition to FLI-I rearrangements, fusion of EWS to the closely related ETS proto-oncogene ERG, located on chromosome 21q22, was revealed in t(ll;22)(q24;qI2)-negative ETs Sorenson et al., 1994) . The positions of the chromosome translocation breakpoints were shown to be restricted to introns 7-10 of the EWS gene and widely dispersed within introns 3-9 of the ETS-related genes. Among the rearrangements that result in in-frame exon fusion, joining of exon 7 of EWS to either exon 6 or 5 of FLI-I has been observed most frequently (81%) . These rearrangements correspond to type I and II fusion transcripts originally reported by Delattre et al. (1992) . Regarding the EWS/ERG rearrangements, four different chimaeic transcripts have been reported so far . The minimal coding sequences present in all El-specific fusion transcripts is composed of EWS exons 1-7 and by the FLI-I or ERG region downstream of the exon 8/9 boundary. These RNAs encode chimaenc proteins with a C-terminal glutamine-nrch EWS regulatory domain (EWS-RD) fused via a variable hinge region to a unique DNA-binding domain that is charcteristic of all ETS transcription factors. The activity of a second transactivating domain, which resides in the C-terminus of FLI-I or ERG, is dependent on the presence of EWS-RD (Ohno et al., 1993) . However, nothing is known about the function and the physiological consequences of the variant region lying in between EWS-RD and the DNA-binding domain, except that type I and a chimaeric transcript 66 bp shorter than type I transform NIH-3T3 cells equally well (May et al., 1993) . We now report on the analysis of different gene fusions and accessory splicing variants in 30 ETs by means of RT-PCR. The molecular data are compared with all relevant clinical data available in order to identify any correlations of specific EWS chimaeric variants with the course of the disease in ET patients.
Materials and methods

Patients and tumours
The tumour-derived material analysed in this study originated from 30 ET patients. 14 females and 16 males with a median age of 13 years (range 3-25) ( (Biomarker, Rehovot, Israel; D-1033, Sigma) , common leucocyte antigen, anti-muscle-specific actin (HHF-35, Enzo, New York, NY, USA), HNK-I/Leu 7 (Becton Dickinson, Sunnyvale, CA, USA), neuron-specific-enolase (Bioscience, Emmenbriicke, Switzerland) and S-100 protein (Dakopatts, Glostrup, Denmark). All tumours were reviewed by the Vienna Bone Tumour Registry (M. Salzer-Kuntschik) and classified as ETs according to the CESS criteria (Juirgens et al., 1988; Ambros et al., 1991) .
Nucleic acid isolation
Total RNAs from frozen tumours or cell lines were isolated using the TRIzol extraction kit (Gibco BRL, Life Technologies, Gaithersburg, MD, USA) based on the acid guanidinium-phenol-chloroform method (Chomczynsli & Sacchi, 1987) .
Reverse transcription and PCR amplification
Aliquots of 1-4 iLg of total RNA were reversed transcribed with either random hexamers, oligo-dT or with the FLI-I specific primer 1 A (Table II) using Moloney munne leukaemia virus reverse transcriptase (Gibco BRL, Life Technologies).
The resulting cDNAs were PCR amplified using primers 11.3 and 22.3 (Delattre et al., 1992) or primers 22.3 and ERG 3 (Table II) . Internal control for specific amplification was provided by nested PCR using primers 11.4 and 22.4 or primers 22.4 and ERG 4. In order to evaluate the quality of Direct sequencing of double-stranded PCR products was carried out using the Femtomole-Sequencing System (finol, Promega). Reaction products were analysed in 8% polyacrylamide gels.
HI-bridisation analysis PCR products were routinely hybridised to EWS-. FLI-1-or ERG-specific probes either in gel or on filters.
For in-gel hybridisation PCR products were electrophoresed through a 2% agarose gel which was dried for I h at room temperature followed by 3 h at 60°C. Dried gels were swollen in water and incubated successively in 0.5 M sodium hydroxide, 0.15 M sodium chloride, and in 0.5 M Tris pH 8.0. 0.15 M sodium chloride, for 30 min, each. Gels were equilibrated in 6 x SSC (I x SSC = 0.15 M sodium chloride, 0.15 M sodium citrate, pH 7.0) for 15 min and hybridised to radiolabelled FLI-I-specific oligonucleotide 11.6 (Table II) for 2-3h at 60°C in 5xSSPE (I xSSPE=0.15M sodium chloride, 0.010 M sodium hydrogen phosphate, 0.001 M EDTA), 5 x Denhardt's solution (I x Denhardt = 0.2 g 1I Ficoll, polyvinylpyrrolidone and bovine serum albumin) and 0.1% SDS followed by 2-3 washes with 6 x SSC.
For filter hybnrdisations gels were blotted onto a nylon membrane (Hybond/Amersham), which was subsequently prehybridised and hybridised to EWS-. FLI-1-or ERGspecific probes according to standard procedures (Maniatis et al., 1982 were detected in 68% and 14% respectively. One tumour expressed a chimaeric transcript combining EWS exon 7 with FLI-I exon 7. which has not been observed before. One tumour displayed a fusion of EWS exon 10 to FLI-I exon 5. RT-PCR analysis of a cell line established from a metastasis from patient 2 resulted in multiple amplification products. In order to discriminate between specific and non-specific bands all fragments were excised from the gel, reamplified using primers 11.4 and 22.4 and subjected to direct sequence analysis (Figure 2) point in EWS intron 9 (0. Delattre, personal communication). Other specific bands could be assigned to EWS/FLI-1 exon combinations 7/4, 7/6, 7/8 and 7/9, the smallest product ever observed (Figure 2a ). Since these results were obtained repeatedly using independent RNA preparations, we do not think that these accessory products resulted from crosscontamination or product carry-over but rather from alternative splicing of the exon 9/4 fusion product. Two patients Finally. RNA extracted from all tumours with a diagnosis other than ET (i.e. three rhabdomyosarcomas, one lymphoma, one neuroblastoma. one osteosarcoma and one malignant melanoma) did not reveal any EWS chimaeric transcript in RT-PCR. A comparison of the distribution of primary tumour sites with the different exon combinations revealed the following (Table III) . The relative frequency of the most common EWSIFLI-I exon combination 7/6 -type I -(19 tumours) was higher in tumours of the extremities (six legs, three arms) than in central axis tumours (four chest wall, three pelvis) or in tumours in other locations (three cases). In contrast EWS exon 7/FLI-1 exon 5 transcripts -type II -(four tumours) were present in tumours of the chest wall and the pelvis (two cases each) only. Studies of the extent of disease showed that 78% (14/18) of patients with localised disease expressed type I RNA. In contrast, type II transcripts predominated in patients with disseminated disease at diagnosis (three cases) as compared with localised tumours (one case). This patient (no. 7) with a thoracopulmonary ET achieved a partial remission after two courses of chemotherapy, but shortly thereafter showed a tumour progression with lung and bone metastases. This tumour displayed a p53 mutation, which is very rare in patients with ET (Kovar et al., 1993) , and this may have been responsible for the aggressive tumour growth.
In this study. EWS chimaeric transcripts were also detected in two patients with extraosseous ET (nos. 22 and 23).
One tumour, evolving from the chest wall with secondary infiltration of the scapula, showed a fusion of EWS and ERG (no. 22) . In the other case (patient 23), ET developed as a secondary malignancy from the iliopsoas muscle after acute lymphoblastic leukaemia and expressed a chimaeric transcript with EWS exon 7 fused to FLI-I exon 7. (Turc-Carel et al., 1988) . This observation might be partially explained by the orientations of the genes involved in the translocations: EWS and FLI-I are orientated from the centromere to the telomere, whereas ERG is orientated from the telomere to the centromere (Crete et al., 1993 Zucman et al. (1993) . The data colleted in our study from a relatively smal number of cases suggest that the EWS/FLI-1 exon combination 7/6 predominates in fusion transcripts of localised tumours of the extremities, whereas the combination EWS exon 7/FLI-1 exon 5 was more frequent in metastatic disease and tumours of the central axis. However, the sigifi of these findings has to be carefully evaluated in much larger cohorts of patients. Moreover, we could demonstrate the presence of a t(11;22Xq24;ql2) and a t(21;22Xq24;q12) in two cases of malignancies of soft tissues at the molecular level, thus confirming the diagnosis of extraosseous ET. One of these tumours, which occurred as a second malignancy after treatment of acute lymphoblastic leukaemia, expressed an EWS/FLI-1 exon 7/7 fusion transcript which has not been reported before and therefore appears to be rare. In another unusual case with a single defined gene rearrangement at the DNA level (data not shown), a large EWS/FLI-1 transcript including EWS exons 1-9 as well as FLI-1 exons 4-9 was coexpressed with a number of deduced splicing variants, all lacking EWS exons 8 and 9 and fused to FLI-I exons 4, 6, 8 or 9. In the protein encoded by the smallest product (EWS/FLI-1 exons 7/9) the EWS regulatory region is directly joined to the FLI-I DNAbinding domain. This product has been predicted to occur as a paralkl to the llt EWS/ERG fusion observed by Zucman et al. (1993) . The coexistence of alternative splicing variants seems to be common in cells carrying chromosomal translocations and has been demonstrated to occur in BCR/ ABL-, PML/RAR-and PBXI/E2A-positive leukaemias (Shtivehman et al., 1986; Solomons et al., 1991; Izraeli et al., 1992) . The possible presence of multiple differentially procesed fusion transcripts in one tumour makes the application of additional methods for specification mandatory. We performed nested PCR as well as hybridisation to FLI-1-and ERG-specific probes and sequence analysis in order to distinguish specific amplification products from non-specific ones. Moreover, these very sensitive methods will be of particular help in the analysis of minimal metastatic and residual disease. The protocol applied in this report allowed detection of one tumour cell in 10' nucleated cells by nested PCR in multiple mixing experiments (C. Pfleiderer et al., manuscript in preparation).
In 
